Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

ClinicalTrials.gov ID: NCT01732913

Public ClinicalTrials.gov record NCT01732913. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Study identification

NCT ID
NCT01732913
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Gilead Sciences
Industry
Enrollment
295 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Rituximab Drug
  • Idelalisib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 15, 2013
Primary completion
May 17, 2016
Completion
May 17, 2016
Last update posted
Nov 15, 2018

2013 – 2016

United States locations

U.S. sites
32
U.S. states
18
U.S. cities
31
Facility City State ZIP Site status
Clearview Cancer Institute Huntsville Alabama 35805
Ironwood Cancer and Research Center Chandler Arizona 85224
City of Hope Cancer Center Duarte California 91010
Saint Jude Heritage Healthcare Fullerton California 92835
Pacific Shores Medical Group Long Beach California 90813
UCLA Medical Center Los Angeles California 90095
Cancer Care Associates Redondo Beach California 90277
Cancer Center of Santa Barbara Santa Barbara California 93105
Central Coast Medical Oncology Group Santa Maria California 93454
Middlesex Hospital Cancer Center Middletown Connecticut 06457
Georgetown University Medical Center Washington D.C. District of Columbia 20007
Florida Cancer Specialists and Research Institute Fort Myers Florida 33916
Moffitt Cancer Center Tampa Florida 33612
Cancer Center of Kansas Wichita Kansas 67214
Wayne State University Detroit Michigan 48201
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169-3321
Icahn School of Medicine at Mount Sinai New York New York 10029
Weill Cornell Medical College New York New York 10065
Montefiore Medical Center The Bronx New York 10467
MetroHealth Medical Center Cleveland Ohio 44109
Signal Point Clinical Research Center, LLC Middletown Ohio 45042
Perelman Center for Advanced Medicine Philadelphia Pennsylvania 19104
Prairie Lakes Healthcare System Watertown South Dakota 57252
Tennessee Oncology, PLLC Chattanooga Tennessee 37404
Sarah Cannon Cancer Center Nashville Tennessee 37203
Texas Oncology, P.A. Bedford Texas 76022
Brooke Army Medical Center Fort Sam Houston Texas 78234
Center for Cancer and Blood Disorders, PC Fort Worth Texas 76104
Shenandoah Oncology Associates, PC Winchester Virginia 22601
Virginia Mason Medical Center Seattle Washington 98101
Northwest Medical Specialties, PLLC Tacoma Washington 98405
Froedtert Hospital and Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01732913, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 15, 2018 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01732913 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →